Circulating cell-free DNA use for diagnosing cholangiocarcinoma

Sorscher, Steven

doi:10.1186/s13148-019-0667-4

Cited by 2 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although cfDNA has been studied extensively in other cancers, 4,[9][10][11] to our knowledge, so far there is no study investigating the diagnostic or prognostic value of cfDNA in resectable CBD cancer. In a study of the influence of fetal sex and maternal characteristics on fetal cfDNA in maternal plasma, Zhao et al 27 found that concentration of female fetal cfDNA was higher than male fetal cfDNA (mean fetal cfDNA, 13.07% vs 8.37%, p < 0.0001).…”

Section: Discussionmentioning

confidence: 99%

“…So far, data regarding diagnosis and prognosis for bile duct cancer are limited, partly because of the rarity of the disease. Although cfDNA has been studied extensively in other cancers, 4,[9][10][11] there is little evidence on the diagnostic or prognostic values of cfDNA in resectable distal common bile duct (CBD) cancer, especially in comparison to traditional serum protein tumor markers, such as carbohydrate antigen and carcinoembryonic antigen (CEA).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cell-Free DNA as a prognostic and predictive biomarker in resectable distal common bile duct cancer

Shyr

Chen

Shyr

et al. 2023

Journal of the Chinese Medical Association

View full text Add to dashboard Cite

Background: Cell-free DNA (cfDNA) as an oncological biomarker has drawn much attention in recent years, but very limited effort has been made to investigate the prognostic values of cfDNA in distal common bile duct (CBD) cancer. Methods: Plasma cfDNA was measured in 67 patients with resectable distal CBD cancer. Survival outcomes and the correlation of cfDNA with other conventional prognostic factors were determined. Results: cfDNA levels were significantly higher in female patients, and those with poor tumor differentiation, abnormal serum carcinoembryonic antigen (CEA) level, and stage III cancer. The significant prognostic factors included a high cfDNA level (>8955 copies/mL), abnormal serum CEA level, stage III cancer, and positive resection margins. Compared with patients with high cfDNA level, those with lower cfDNA level (≤8955 copies/mL) had significantly better overall survival outcomes (74.4% vs 100% and 19.2% vs 52.6%, for 1-and 5-year survival rates, respectively, p = 0.001). The cfDNA level, perineural invasion, CEA level, and radicality were identified as independent prognostic factors for distal CBD cancer after multivariate analysis. Conclusion: Circulating cfDNA levels play a significant role in predicting the prognosis and survival outcome for resectable distal CBD cancer. Furthermore, acting as a promising liquid biopsy, cfDNA could serve as a prognostic and predictive biomarker in combination with current conventional markers to improve diagnostic and prognostic efficacy.

show abstract